International Multiconference “Bioinformatics of Genome Regulation and Structure\Systems Biology”

Tag

TCGA

2 RESULTS
Genomics, transcriptomics, bioinformatics symposiumDifferentially expressed genes associated with TMPRSS2-ERG molecular subtype of prostate cancer

Differentially expressed genes associated with TMPRSS2-ERG molecular subtype of prostate cancer

No Comment on Differentially expressed genes associated with TMPRSS2-ERG molecular subtype of prostate cancer

Poster (download)

[pdf-embedder url=”https://bgrssb.icgbio.ru/wp-content/uploads/2020/07/256.pdf”]
Anastasiya Andreevna Kobelyatskaya1, Elena Anatolevna Pudova2, George Sergeevich Krasnov3, Anna Victorovna Kudryavtseva4, Kirill Mikhailovich Nyushko5, Boris Yakovlevich Alekseev6
1EIMB RAS, kaa.chel@mail.ru
2EIMB RAS, pudova_elena@inbox.ru
3EIMB RAS, gskrasnov@mail.ru
4EIMB RAS, rhizamoeba@mail.ru
5FSBI NMRRC, kirandja@yandex.ru
6FSBI NMRRC, mnioi@mail.ru

Prostate cancer (PC) is one of the most common and socially significant oncological diseases in men. This study examined the transcriptome profile of the most common molecular genetic subtype of prostate cancer, TMPRSS2-ERG. As a result of bioinformatics analysis conducted on the basis of The Cancer Genome Atlas project data, 115 differentially expressed genes were identified for this study group, and in particular, the most over-expressing genes were identified: ALOX15, CACNA1D, EML6, HLA-DMB, NKAIN1, OGDHL, PLA1A, SYT13. Enrichment pathways analysis showed that these genes are participants in important oncologically significant pathways, which emphasizes the association of this molecular subtype with an unfavorable prognosis for prostate cancer.

Genomics, transcriptomics, bioinformatics symposiumIntermediate and high-risk prostate cancer methylation analysis

Intermediate and high-risk prostate cancer methylation analysis

No Comment on Intermediate and high-risk prostate cancer methylation analysis

Poster (download)

[pdf-embedder url=”https://bgrssb.icgbio.ru/wp-content/uploads/2020/07/262.pdf”]
Elena Pudova1
1EIMB RAS, pudova_elena@inbox.ru

Prostate cancer is one of the most important socially significant oncological diseases in men. To select an effective approach to therapy, prostate cancer is stratified into appropriate risk groups based on criteria such as TNM status, Gleason score and the level of prostate-specific antigen (PSA). However, to optimize therapy, additional informative markers are necessary, and the aim of this study is to search for these markers at the level of genome methylation. This work included methylation data of prostate cancer from The Cancer Genome Atlas project. The cohort involved patients with high (23 cases) and intermediate (103 cases) risk. As a result, 1,056 differentially methylated CpG sites were found between high and medium risk groups. CpG most interested sites: cg17687367 (chr13: 79936801), cg26874611 (chr5: 168147884), cg06989693 (chr5: 41409252), cg02226810 (chr6: 1605117), cg07736716 (regulation regions: 85): 85 to 91 (85): 85 858: 858: 858: 85: 86: 85: 86: 85: 86: 85: 86: 85: 86: 85: 85.